Metrovacesa Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Metrovacesa heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 54.1%, terwijl de Real Estate-industrie de winst zag groeien met 11.5% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 16.4%. Het rendement op eigen vermogen van Metrovacesa is 4%, en het heeft een nettomarge van 8%.
Belangrijke informatie
54.14%
Groei van de winst
61.06%
Groei van de winst per aandeel
| Real Estate Groei van de industrie | 17.43% |
| Inkomstengroei | 16.39% |
| Rendement op eigen vermogen | 4.02% |
| Nettomarge | 8.03% |
| Volgende winstupdate | 22 Jul 2026 |
Recente prestatie-updates uit het verleden
Analyseartikel • Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...Analyseartikel • Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...Recent updates
Narratiefupdate • Jun 11
MVC: Slightly Lower Required Return And Rich P/E Will Shape Future Upside
Analysts now cite a slightly higher fair value per share for Metrovacesa, lifting their price target from €11.17 to €11.28. This revision is supported by small refinements to assumptions for the discount rate, revenue growth, profit margin and future P/E.Narratiefupdate • May 28
MVC: Slightly Lower Required Return And Rich P/E Will Shape Future Upside
Analysts have nudged their fair value estimate for Metrovacesa to €11.17 from €10.81, citing updated assumptions around the discount rate and future P/E, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: €11.17, up slightly from €10.81.Narratiefupdate • May 02
MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside
Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.Narratiefupdate • Apr 17
MVC: Higher Required Return And Rich P/E Will Pressure Future Returns
Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.Narratiefupdate • Apr 03
MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns
Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.Narratiefupdate • Mar 20
MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance
Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.
Narratiefupdate • Mar 06
MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View
Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.Narratiefupdate • Feb 20
MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance
Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.Narratiefupdate • Feb 06
MVC: Lower Discount Rate And High P/E Will Sustain Bearish View
Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.Narratiefupdate • Jan 23
MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook
Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).
Narratiefupdate • Jan 08
MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis
Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.Narratiefupdate • Dec 24
MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook
Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.Analyseartikel • Dec 20
Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate
Key Insights Metrovacesa's estimated fair value is €11.52 based on 2 Stage Free Cash Flow to Equity Current share price...Narratiefupdate • Dec 10
MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects
Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.Analyseartikel • Oct 02
Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?
Metrovacesa S.A. ( BME:MVC ), is not the largest company out there, but it had a relatively subdued couple of weeks in...Analyseartikel • Jul 25
Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €12.58 Metrovacesa's €10.15...Analyseartikel • May 04
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Apr 12
Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?
Key Insights The projected fair value for Metrovacesa is €16.96 based on 2 Stage Free Cash Flow to Equity Metrovacesa...Analyseartikel • Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
Nieuw narratief • Feb 19
Will Leverage Undersupplied Spanish Housing Market For Future Opportunities
High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.Analyseartikel • Feb 07
Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it maintained its current share price...Analyseartikel • Dec 13
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued
Key Insights Metrovacesa's estimated fair value is €16.39 based on 2 Stage Free Cash Flow to Equity Metrovacesa's €9.13...Analyseartikel • Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.93 based on 2 Stage Free Cash Flow to Equity Metrovacesa's...Analyseartikel • Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...Analyseartikel • Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it saw significant share price...Analyseartikel • May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €9.31 Current share price...Analyseartikel • May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it received a lot of attention from a...Analyseartikel • Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.08 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it saw significant share...Analyseartikel • Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €7.36 Current share price...Analyseartikel • Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it received a lot of...Analyseartikel • May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Does the May share price for Metrovacesa S.A. ( BME:MVC ) reflect what it's really worth? Today, we will estimate the...Analyseartikel • Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality
Metrovacesa S.A. ( BME:MVC ) just reported healthy earnings but the stock price didn't move much. We think that...Analyseartikel • Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyseartikel • Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?
Today we will run through one way of estimating the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by projecting its...Analyseartikel • May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?
Is Metrovacesa S.A. ( BME:MVC ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...Analyseartikel • Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 12% in the last month. But that...Analyseartikel • Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven
We feel now is a pretty good time to analyse Metrovacesa S.A.'s ( BME:MVC ) business as it appears the company may be...Analyseartikel • Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?
Metrovacesa S.A. ( BME:MVC ), might not be a large cap stock, but it led the BME gainers with a relatively large price...Analyseartikel • Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
In this article we are going to estimate the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by taking the expected...Analyseartikel • Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 11% in the last month. But that...Opbrengsten en kosten
Opbrengsten en kosten
Hoe Metrovacesa geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 25 | 708 | 57 | 51 | 0 |
| 30 Sep 25 | 632 | 27 | 51 | 0 |
| 30 Jun 25 | 555 | -3 | 51 | 0 |
| 31 Mar 25 | 604 | 6 | 52 | 0 |
| 31 Dec 24 | 653 | 16 | 54 | 0 |
| 30 Sep 24 | 651 | 17 | 53 | 0 |
| 30 Jun 24 | 649 | 18 | 53 | 0 |
| 31 Mar 24 | 616 | -15 | 53 | 0 |
| 31 Dec 23 | 581 | -21 | 52 | 0 |
| 30 Sep 23 | 535 | -68 | 51 | 0 |
| 30 Jun 23 | 430 | -71 | 52 | 0 |
| 31 Mar 23 | 454 | -38 | 51 | 0 |
| 31 Dec 22 | 516 | -23 | 51 | 0 |
| 30 Sep 22 | 529 | 25 | 57 | 0 |
| 30 Jun 22 | 572 | 33 | 56 | 0 |
| 31 Mar 22 | 575 | 31 | 55 | 0 |
| 31 Dec 21 | 512 | 18 | 53 | 0 |
| 30 Sep 21 | 413 | -71 | 47 | 0 |
| 30 Jun 21 | 231 | -90 | 40 | 0 |
| 31 Mar 21 | 138 | -160 | 34 | 0 |
| 31 Dec 20 | 140 | -164 | 34 | 0 |
| 30 Sep 20 | 164 | -87 | 34 | 0 |
| 30 Jun 20 | 180 | -87 | 34 | 0 |
| 31 Mar 20 | 214 | -6 | 35 | 0 |
| 31 Dec 19 | 161 | -4 | 34 | 0 |
| 30 Sep 19 | 206 | 0 | 33 | 0 |
| 30 Jun 19 | 220 | 5 | 31 | 0 |
| 31 Mar 19 | 211 | -11 | 28 | 0 |
| 31 Dec 18 | 190 | -9 | 29 | 0 |
| 30 Sep 18 | 103 | -14 | 23 | 0 |
| 30 Jun 18 | 70 | -31 | 26 | 0 |
| 31 Mar 18 | 34 | -34 | 18 | 0 |
| 31 Dec 17 | 28 | -39 | 15 | 0 |
| 30 Sep 17 | 29 | -55 | 11 | 0 |
| 31 Dec 16 | 21 | -21 | 7 | 0 |
| 31 Dec 15 | 36 | 64 | 8 | 0 |
Kwaliteitswinsten: MVC heeft een grote eenmalige verlies van €36.9M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 31st December, 2025.
Groeiende winstmarge: De huidige netto winstmarges (8%) MVC } zijn hoger dan vorig jaar (2.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MVC is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 54.1% per jaar laten groeien.
Versnelling van de groei: De winstgroei van MVC over het afgelopen jaar ( 257.9% ) overtreft het 5-jarig gemiddelde ( 54.1% per jaar).
Winst versus industrie: De winstgroei MVC over het afgelopen jaar ( 257.9% ) overtrof de Real Estate -sector 73.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 4% ) van MVC wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/29 11:56 |
| Aandelenkoers aan het einde van de dag | 2026/06/26 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Metrovacesa S.A. wordt gevolgd door 21 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ignacio Romero | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Mariano Miguel Hidalgo | Banco Santander |